Australia And Newzealand Diabetes Devices Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The Australia and New Zealand diabetes devices market covers products across monitoring devices, management and insulin delivery devices, and related consumables. The combined market was valued at approximately $1.17 billion in 2025, with forecasts pointing toward $1.30 billion by 2029 and $1.37 billion by 2031. Australia accounts for the overwhelming majority of regional market value, with its domestic segment alone estimated at approximately $721.44 million in 2025.

• •Australia's National Diabetes Services Scheme (NDSS) provides publicly subsidized access to diabetes devices for eligible patients, underpinning much of the market's accessibility and growth
• •The market spans continuous glucose monitors, flash glucose monitors, traditional blood glucose meters, insulin pumps, and related disposable consumables
• •New Zealand operates a smaller but functional diabetes device market, with public health funding through Pharmac supporting access to selected devices

Rising prevalence of both type 1 and type 2 diabetes across Australia and New Zealand is expanding the addressable patient population requiring glucose monitoring and insulin delivery devices. Expansion of CGM reimbursement through Australia's NDSS, progressively widening eligibility criteria, has substantially reduced out-of-pocket costs and accelerated adoption of continuous monitoring technology.

• •Australia's aging population and rising obesity rates are contributing to increasing type 2 diabetes incidence, broadening demand across monitoring and management device categories
• •NDSS-funded CGM access for eligible type 1 diabetes patients and, more recently, select type 2 patients on intensive insulin therapy has been a key catalyst for market expansion
• •Growing clinical and health economic evidence supporting the benefits of continuous glucose monitoring in improving glycemic control and reducing complications

The market is segmented into monitoring devices, management devices, and supporting consumables, with continuous glucose monitoring systems representing the fastest-growing subcategory. Monitoring devices, including CGMs, flash glucose monitors, and traditional test strips, form the largest product segment, while insulin pumps and smart delivery systems are gaining share within management devices.

• •Australia dominates the combined ANZ market, representing an estimated 60-65% share based on its larger population, higher diabetes prevalence, and more extensive publicly funded device access
• •New Zealand's smaller population base yields a proportionally smaller market, though public funding via Pharmac and private insurance pathways support consistent, if modest, growth
• •Blood glucose monitoring (traditional test strips and meters) still accounts for significant volume, but CGM adoption is rapidly shifting market share toward continuous monitoring solutions

What are the recent trends and outlook?

The market is expected to sustain steady growth through 2031, underpinned by continued public funding support, ongoing product innovation, and the broader shift toward digital and connected diabetes management. Integration of smartphones, AI-driven glucose trend analysis, and hybrid closed-loop automated insulin delivery systems represent the most significant technological trends reshaping the competitive landscape.

• •Hybrid closed-loop (automated insulin delivery or 'artificial pancreas') systems are expected to gain traction as reimbursement pathways evolve and clinician and patient awareness increases
• •Digital health integration, including smartphone-connected devices, telehealth-enabled diabetes management, and cloud-based data sharing, is accelerating across both Australian and New Zealand markets
• •As CGM becomes the standard of care, the market is undergoing a structural shift away from intermittent finger-stick testing toward continuous monitoring, reshaping product mix and competitive dynamics